2898 T3D2856 Sumatriptan Sumatriptan is an exogenous organic compound with the formula C14H21N3O2S and an average molecular weight of 295.40 g/mol. It exists as a solid at room temperature. Sumatriptan belongs to the tryptamines and derivatives, a subclass of indoles and derivatives within the organic compounds. This compound is classified as a serotonergic agonist and a vasoconstrictor agent. It has been detected in brain tissue. Sumatriptan targets 13 proteins, including 5-hydroxytryptamine receptor 1A (HTR1A), 5-hydroxytryptamine receptor 1B (HTR1B), 5-hydroxytryptamine receptor 1D (HTR1D), 5-hydroxytryptamine receptor 1E (HTR1E), 5-hydroxytryptamine receptor 1F (HTR1F), 5-hydroxytryptamine receptor 2A (HTR2A), 5-hydroxytryptamine receptor 2B (HTR2B), and 5-hydroxytryptamine receptor 2C (HTR2C). Sumatriptan stimulates 5-HT receptors of the 1D subtype, most likely presynaptic receptors, resulting in selective vasoconstriction of inflamed and dilated cranial blood vessels in the carotid circulation. Additionally, it blocks the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during migraine and may inhibit the release of inflammatory mediators from the trigeminal nerve. The compound is used in the treatment of migraines. It is recorded in 18 sources, including healthcare, pharmaceuticals & veterinary products (analgesics and gynecologicals), household cleaning & consumer products (such as soap detergents, perfumes within detergents and soaps, cigar cigarettes, non electric simulated smoking devices, and other smoking requisites), electrical & electronic equipment (including antennas, conductors or conductive bodies characterised by the conductive materials, electric hearing aids, electric switches, and electrically stimulated smoking devices), building & construction (floors), and food, food processing & cookware (food preservation). Recorded exposure routes include oral, nasal, subcutaneous, topical, and transdermal. 103628-46-2 5358 C14H21N3O2S 295.135450 White powder. 169-171°C 21.4 mg/ml Subcutaneous, Oral, Nasal, Transdermal The 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors function as autoreceptors, which inhibit the firing of serotonin neurons and a reduction in the synthesis and release of serotonin upon activation. After sumatriptan binds to these receptors, adenylate cyclase activity is inhibited via regulatory G proteins, incrases intracellular calcium, and affects other intracellular events. This results in vasoconstriction and inhibtion of sensory nociceptive (trigeminal) nerve firing and vasoactive neuropeptide release. Sumatriptan stimulates 5-HT receptors of the 1D subtype, most likely presynaptic receptors, resulting in selective vasoconstriction of inflamed and dilated cranial blood vessels in the carotid circulation. Sumatriptan also blocks the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during migraine and may inhibit the release of inflammatory mediators from the trigeminal nerve. Hepatic. In vitro studies with human microsomes suggest that sumatriptan is metabolized by monoamine oxidase (MAO), predominantly the A isoenzyme. Route of Elimination: Only 3% of the dose is excreted in the urine as unchanged sumatriptan; 42% of the dose is excreted as the major metabolite, the indole acetic acid analogue of sumatriptan. Half Life: 2.5 hours No indication of carcinogenicity to humans (not listed by IARC). For the treatment of migraine attacks with or without aura. Symptoms of overdose include convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation, and lacrimation. 2009-07-21T20:27:23Z 2026-05-14T16:45:35Z Sumatriptan C07319 10650 Sumatriptan DB00669 true CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1 C14H21N3O2S InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3 KQKPFRSPSRPDEB-UHFFFAOYSA-N 295.4 295.135447621 Exogenous Solid 0.93 HMDB05037 CHEMBL128 5165 <p>Rajeev Mathur, T. Kumar, Sunilendu Roy, Rajiv Malik, &#8220;Taste masked sumatriptan tablets and processes for their preparation.&#8221; U.S. Patent US20060233875, issued October 19, 2006.</p> CHEM002244 DTXSID4023628 NS00009397 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide 65.2 82.08419999999998 32.30534147835603 5 3 2 11.244987975521886 9.536988551879368 1 2 1.17 -3.37 1.27e-01 g/l Organic compounds Organoheterocyclic compounds Indoles and derivatives Tryptamines and derivatives 3515 CED0003888 KQKPFRSPSRPDEB-UHFFFAOYSA-N 40000000000000000008000020001000000000000600000000000000000000000004000000002000080000200080000000000000000000000200008000000000000000000000400000000000000000000280000000004000000000000000000000000000200000000000000001040000080000000000000000000000000000000000000400000000000002000000000801000000000000000000010000000000000000000000000040400000800000000000200000000000800000000000000100000000000000000000000000000000010000000000000000002a0000000000000000000000000000041000000000000005001000000000000000000000000 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 776t3gAAAAAQAAAAAwAAAAAAAAAUAAAAFQAAAIABBgBgAAAAAQMHAGAAAAAC ARAAIAAAAAYIACgAAAADAggAKAAAAAMCBgBgAAAAAgIGQCgAAAADBAZAaAAA AAMDAQZAKAAAAAMEBkAoAAAAAwQHQDgAAAADAQMGQGgAAAADAwEGQCgAAAAD BAYAYAAAAAICBgBgAAAAAgIHACAAAAADBgBgAAAAAQMGAGAAAAABAwZAaAAA AAMDAQZAaAAAAAMDAQsAAQABAgACAwgCAgQIAgIFAAUGAAYHaAwHCGgMCAlo DAkKaAwKC2gMCwxoDAwNAA0OAA4PAA8QAA8RAAkSaAwSE2gMEwZoDAwIaAxC AgAAAAYGExIJCAcFCgkIDAsXBAAAAAAAAAAW 2026-09-19T04:00:37Z